The impact of new (orphan) drug approvals on premature mortality from rare diseases in the United States and France, 1999–2007
Download
Download
Download
Full text for this resource is not available from the Research Repository.
Export
Lichtenberg, Frank R (2013) The impact of new (orphan) drug approvals on premature mortality from rare diseases in the United States and France, 1999–2007. European Journal of Health Economics, 14 (1). pp. 41-56. ISSN 1618-7598
Dimensions Badge
Altmetric Badge
| Item type | Article |
| URI | https://vuir.vu.edu.au/id/eprint/40451 |
| DOI | 10.1007/s10198-011-0349-4 |
| Official URL | https://link.springer.com/article/10.1007/s10198-0... |
| Subjects | Historical > FOR Classification > 1402 Applied Economics Historical > FOR Classification > 1605 Policy and Administration Historical > Faculty/School/Research Centre/Department > College of Business |
| Keywords | orphan diseases; orphan drugs; drug approval; pharmaceutical innovation; econometric model |
| Citations in Scopus | 18 - View on Scopus |
| Download/View statistics | View download statistics for this item |
CORE (COnnecting REpositories)